Research News

Risk of breast cancer recurrence remains for years after endocrine treatment ends, study finds

BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j5167 (Published 08 November 2017) Cite this as: BMJ 2017;359:j5167
  1. Susan Mayor
  1. London

Women treated for oestrogen receptor (ER) positive breast cancer have a persistent risk of recurrence for at least 15 years after being disease free with the current standard of five years’ endocrine therapy, a large meta-analysis of long term follow-up studies has reported.1

“This finding has implications for long term follow-up strategies and highlights the need for new approaches to reduce late recurrence,” the researchers, led by Hongchao Pan, from the University of Oxford, UK, said. They added, “The risk could be reduced by extending the duration of …

View Full Text

Sign in

Log in through your institution

Subscribe